171 related articles for article (PubMed ID: 30025346)
1. Biological activity of doubly modified salinomycin analogs - Evaluation in vitro and ex vivo.
Antoszczak M; Urbaniak A; Delgado M; Maj E; Borgström B; Wietrzyk J; Huczyński A; Yuan Y; Chambers TC; Strand D
Eur J Med Chem; 2018 Aug; 156():510-523. PubMed ID: 30025346
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Anticancer Activity of Tertiary Amides of Salinomycin and Their C20-oxo Analogues.
Czerwonka D; Urbaniak A; Sobczak S; Piña-Oviedo S; Chambers TC; Antoszczak M; Huczyński A
ChemMedChem; 2020 Jan; 15(2):236-246. PubMed ID: 31702860
[TBL] [Abstract][Full Text] [Related]
3. Synthetic modification of salinomycin: selective O-acylation and biological evaluation.
Borgström B; Huang X; Pošta M; Hegardt C; Oredsson S; Strand D
Chem Commun (Camb); 2013 Nov; 49(85):9944-6. PubMed ID: 24037337
[TBL] [Abstract][Full Text] [Related]
4. Semisynthesis of SY-1 for investigation of breast cancer stem cell selectivity of C-ring-modified salinomycin analogues.
Huang X; Borgström B; Månsson L; Persson L; Oredsson S; Hegardt C; Strand D
ACS Chem Biol; 2014 Jul; 9(7):1587-94. PubMed ID: 24841425
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs.
Huang X; Borgström B; Kempengren S; Persson L; Hegardt C; Strand D; Oredsson S
BMC Cancer; 2016 Feb; 16():145. PubMed ID: 26906175
[TBL] [Abstract][Full Text] [Related]
6. Semi-synthetic salinomycin analogs exert cytotoxic activity against human colorectal cancer stem cells.
Klose J; Kattner S; Borgström B; Volz C; Schmidt T; Schneider M; Oredsson S; Strand D; Ulrich A
Biochem Biophys Res Commun; 2018 Jan; 495(1):53-59. PubMed ID: 29107689
[TBL] [Abstract][Full Text] [Related]
7. Ester derivatives of salinomycin efficiently eliminate breast cancer cells via ER-stress-induced apoptosis.
Kuran D; Flis S; Antoszczak M; Piskorek M; Huczyński A
Eur J Pharmacol; 2021 Feb; 893():173824. PubMed ID: 33347821
[TBL] [Abstract][Full Text] [Related]
8. Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro.
Urbaniak A; Delgado M; Antoszczak M; Huczyński A; Chambers TC
Biomed Pharmacother; 2018 Mar; 99():384-390. PubMed ID: 29367107
[TBL] [Abstract][Full Text] [Related]
9. Singly and doubly modified analogues of C20-epi-salinomycin: A new group of antiparasitic agents against Trypanosoma brucei.
Czerwonka D; Barcelos Y; Steverding D; Cioch A; Huczyński A; Antoszczak M
Eur J Med Chem; 2021 Jan; 209():112900. PubMed ID: 33071053
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative activity of salinomycin and its derivatives.
Huczyński A; Janczak J; Antoszczak M; Wietrzyk J; Maj E; Brzezinski B
Bioorg Med Chem Lett; 2012 Dec; 22(23):7146-50. PubMed ID: 23079523
[TBL] [Abstract][Full Text] [Related]
11. Activity of singly and doubly modified derivatives of C20-epi-salinomycin against Staphylococcus strains.
Czerwonka D; Podsiad M; Stefańska J; Antoszczak M; Huczyński A
J Antibiot (Tokyo); 2022 Aug; 75(8):445-453. PubMed ID: 35760901
[TBL] [Abstract][Full Text] [Related]
12. Salinomycin efficiency assessment in non-tumor (HB4a) and tumor (MCF-7) human breast cells.
Niwa AM; D Epiro GF; Marques LA; Semprebon SC; Sartori D; Ribeiro LR; Mantovani MS
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):557-71. PubMed ID: 26932586
[TBL] [Abstract][Full Text] [Related]
13. Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.
Liu L; Wang Q; Mao J; Qin T; Sun Y; Yang J; Han Y; Li L; Li Q
Chem Biol Interact; 2018 Dec; 296():145-153. PubMed ID: 30273566
[TBL] [Abstract][Full Text] [Related]
14. Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.
Urbaniak A; Reed MR; Fil D; Moorjani A; Heflin S; Antoszczak M; Sulik M; Huczyński A; Kupsik M; Eoff RL; MacNicol MC; Chambers TC; MacNicol AM
Biomed Pharmacother; 2021 Sep; 141():111815. PubMed ID: 34130123
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study.
Michalak M; Lach MS; Antoszczak M; Huczyński A; Suchorska WM
Molecules; 2020 Jan; 25(3):. PubMed ID: 31991882
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activity of Polyether Ionophore-Salinomycin.
Antoszczak M; Huczyński A
Anticancer Agents Med Chem; 2015; 15(5):575-91. PubMed ID: 25553435
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of salinomycin triazole analogues as anticancer agents.
Huang M; Deng Z; Tian J; Liu T
Eur J Med Chem; 2017 Feb; 127():900-908. PubMed ID: 27876192
[TBL] [Abstract][Full Text] [Related]
18. Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.
Kim KY; Kim SH; Yu SN; Park SK; Choi HD; Yu HS; Ji JH; Seo YK; Ahn SC
Mol Med Rep; 2015 Aug; 12(2):1898-904. PubMed ID: 25892525
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, antiproliferative and antibacterial activity of new amides of salinomycin.
Antoszczak M; Maj E; Stefańska J; Wietrzyk J; Janczak J; Brzezinski B; Huczyński A
Bioorg Med Chem Lett; 2014 Apr; 24(7):1724-9. PubMed ID: 24631190
[TBL] [Abstract][Full Text] [Related]
20. Salinomycin reduces growth, proliferation and metastasis of cisplatin resistant breast cancer cells via NF-kB deregulation.
Tyagi M; Patro BS
Toxicol In Vitro; 2019 Oct; 60():125-133. PubMed ID: 31077746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
